Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Leaders in the weight-loss drug market Novo Nordisk have made headlines in the last year with the acquisition of CDMO Catalent by holding company Novo Holdings, as well as signing a deal with biotechnology company Ascendis Pharma to access their delivery technologies in long-acting GLP-1 drugs [12]
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure
IUPAC Compendium of Chemical Terminology
it is a safety-signal literature attached to an unregulated product of unverified content
US$ 26.77
US$ 22.73
US$ 22.09
US$ 23.14
US$ 23.10
US$ 28.87
